Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.
Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. [electronic resource]
- Archives of ophthalmology (Chicago, Ill. : 1960) Jul 1997
- 865-72 p. digital
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0003-9950
10.1001/archopht.1997.01100160035005 doi
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Choroid--blood supply
Choroid Diseases--diagnosis
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Interferon alpha-2
Interferon-alpha--therapeutic use
Macular Degeneration--complications
Male
Middle Aged
Neovascularization, Pathologic--diagnosis
Recombinant Proteins
Safety
Treatment Outcome
Visual Acuity
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0003-9950
10.1001/archopht.1997.01100160035005 doi
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Choroid--blood supply
Choroid Diseases--diagnosis
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Interferon alpha-2
Interferon-alpha--therapeutic use
Macular Degeneration--complications
Male
Middle Aged
Neovascularization, Pathologic--diagnosis
Recombinant Proteins
Safety
Treatment Outcome
Visual Acuity